Background This study evaluated the effects of a mobile diabetes management program called “iCareD” (College of Medicine, The Catholic University of Korea) which was integrated into the hospital’s electronic medical records system to minimize the workload of the healthcare team in the real clinical practice setting.
Methods In this retrospective observational study, we recruited 308 patients. We categorized these patients based on their compliance regarding their use of the iCareD program at home; compliance was determined through self-monitored blood glucose inputs and message subscription rates. We analyzed changes in the ABC (hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol) levels from the baseline to 12 months thereafter, based on the patients’ iCareD usage patterns.
Results The patients comprised 92 (30%) non-users, 170 (55%) poor-compliance users, and 46 (15%) good-compliance users; the ABC target achievement rate showed prominent changes in good-compliance groups from baseline to 12 months (10.9% vs. 23.9%, P<0.05), whereas no significant changes were observed for poor-compliance users and non-users (13.5% vs. 18.8%, P=0.106; 20.7% vs. 14.1%, P=0.201; respectively).
Conclusion Implementing the iCareD can improve the ABC levels of patients with diabetes with minimal efforts of the healthcare team in real clinical settings. However, the improvement of patients’ compliance concerning the use of the system without the vigorous intervention of the healthcare team needs to be solved in the future.
Previous studies have consistently demonstrated the positive effects of continuous glucose monitoring (CGM) on glycemic outcomes and complications of diabetes in people with type 1 diabetes. Guidelines now consider CGM to be an essential and cost-effective device for managing type 1 diabetes. As a result, insurance coverage for it is available. Evidence supporting CGM continues to grow and expand to broader populations, such as pregnant people with type 1 diabetes, people with type 2 diabetes treated only with basal insulin therapy, and even type 2 diabetes that does not require insulin treatment. However, despite the significant risk of hyperglycemia in pregnancy, which leads to complications in more than half of affected newborns, CGM indications and insurance coverage for those patients are unresolved. In this review article, we discuss the latest evidence for using CGM to offer glycemic control and reduce perinatal complications, along with its cost-effectiveness in pregestational type 1 and type 2 diabetes and gestational diabetes mellitus. In addition, we discuss future prospects for CGM coverage and indications based on this evidence.
Citations
Citations to this article as recorded by
Wearable devices for glucose monitoring: A review of state-of-the-art technologies and emerging trends Mohammad Mansour, M. Saeed Darweesh, Ahmed Soltan Alexandria Engineering Journal.2024; 89: 224. CrossRef
Diagnosis and Treatment of Hyperglycemia in Pregnancy Sneha Mohan, Aoife M. Egan Endocrinology and Metabolism Clinics of North America.2024; 53(3): 335. CrossRef
Guidelines for the management of patients with diabetes have become an important part of clinical practice that improve the quality of care and help establish evidence-based medicine in this field. With rapidly accumulating evidence on various aspects of diabetes care, including landmark clinical trials of treatment agents and newer technologies, timely updates of the guidelines capture the most current state of the field and present a consensus. As a leading academic society, the Korean Diabetes Association publishes practice guidelines biennially and the American Diabetes Association does so annually. In this review, we summarize the key changes suggested in the most recent guidelines. Some of the important updates include treatment algorithms emphasizing comorbid conditions such as atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in the selection of anti-diabetic agents; wider application of continuous glucose monitoring (CGM), insulin pump technologies and indices derived from CGM such as time in range; more active screening of subjects at high-risk of diabetes; and more detailed individualization in diabetes care. Although there are both similarities and differences among guidelines and some uncertainty remains, these updates provide a good approach for many clinical practitioners who are battling with diabetes.
Citations
Citations to this article as recorded by
Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes Subo Dey, Jasmine Garg, Andy Wang, Eva Holzner, William H. Frishman, Wilbert S. Aronow Cardiology in Review.2024; 32(3): 285. CrossRef
Use of Diabetes Medications before and after a Heart Failure–Related Hospitalization among Nursing Home Residents Tingting Zhang, Andrew R. Zullo, Kaleen (Kaley) N. Hayes, Dae Hyun Kim, Yoojin Lee, Lori A. Daiello, Douglas P. Kiel, Sarah D. Berry Journal of the American Medical Directors Association.2024; 25(3): 454. CrossRef
Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System Kyung-Soo Kim, Seung-Hwan Lee, Won Sang Yoo, Cheol-Young Park Diabetes Technology & Therapeutics.2024; 26(4): 222. CrossRef
Body composition and metabolic syndrome in patients with type 1 diabetes Qiong Zeng, Xiao-Jing Chen, Yi-Ting He, Ze-Ming Ma, Yi-Xi Wu, Kun Lin World Journal of Diabetes.2024; 15(1): 81. CrossRef
The best internal structure of the Diabetes Quality of Life Measure (DQOL) in Brazilian patients Denilson Menezes Almeida, Aldair Darlan Santos-de-Araújo, José Mário Costa Brito Júnior, Marcela Cacere, André Pontes-Silva, Cyrene Piazera Costa, Maria Cláudia Gonçalves, José Márcio Soares Leite, Almir Vieira Dibai-Filho, Daniela Bassi-Dibai BMC Public Health.2024;[Epub] CrossRef
Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee The Journal of Clinical Endocrinology & Metabolism.2024;[Epub] CrossRef
SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka Prospects in Pharmaceutical Sciences.2024; 22(1): 16. CrossRef
Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial Ji Yoon Kim, Sang-Man Jin, Eun Seok Kang, Soo Heon Kwak, Yeoree Yang, Jee Hee Yoo, Jae Hyun Bae, Jun Sung Moon, Chang Hee Jung, Ji Cheol Bae, Sunghwan Suh, Sun Joon Moon, Sun Ok Song, Suk Chon, Jae Hyeon Kim Diabetologia.2024; 67(7): 1235. CrossRef
Continuous glucose monitoring data for artificial intelligence-based predictive glycemic event: A potential aspect for diabetic care Lim Pei Ying, Oh Xin Yin, Ong Wei Quan, Neha Jain, Jayashree Mayuren, Manisha Pandey, Bapi Gorain, Mayuren Candasamy International Journal of Diabetes in Developing Countries.2024;[Epub] CrossRef
Optimizing postprandial glucose prediction through integration of diet and exercise: Leveraging transfer learning with imbalanced patient data Shinji Hotta, Mikko Kytö, Saila Koivusalo, Seppo Heinonen, Pekka Marttinen, Everson Nunes PLOS ONE.2024; 19(8): e0298506. CrossRef
Diet and gut microbiome: Impact of each factor and mutual interactions on prevention and treatment of type 1, type 2, and gestational diabetes mellitus Davide Menafra, Mattia Proganò, Nicola Tecce, Rosario Pivonello, Annamaria Colao Human Nutrition & Metabolism.2024; 38: 200286. CrossRef
A nationwide cohort study on diabetes severity and risk of Parkinson disease Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim npj Parkinson's Disease.2023;[Epub] CrossRef
Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus Ji Yoon Kim, Nam Hoon Kim Diabetes & Metabolism Journal.2023; 47(1): 42. CrossRef
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Impact of mental disorders on the risk of heart failure among Korean patients with diabetes: a cohort study Tae Kyung Yoo, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee Cardiovascular Diabetology.2023;[Epub] CrossRef
Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko BMC Public Health.2023;[Epub] CrossRef
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key Marta Alonso-Peña, Maria Del Barrio, Ana Peleteiro-Vigil, Carolina Jimenez-Gonzalez, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Paula Iruzubieta, Javier Crespo International Journal of Molecular Sciences.2023; 24(13): 10718. CrossRef
Association between type 2 diabetes mellitus and depression among Korean midlife women: a cross-sectional analysis study You Lee Yang, Eun-Ok Im, Yunmi Kim BMC Nursing.2023;[Epub] CrossRef
Access to novel anti-diabetic agents in resource limited settings: A brief commentary Poobalan Naidoo, Kiolan Naidoo, Sumanth Karamchand, Rory F Leisegang World Journal of Diabetes.2023; 14(7): 939. CrossRef
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis Tirath Patel, Fnu Nageeta, Rohab Sohail, Tooba Shaukat Butt, Shyamala Ganesan, Fnu Madhurita, Muhammad Ahmed, Mahrukh Zafar, Wirda Zafar, Mohammad Uzair Zaman, Giustino Varrassi, Mahima Khatri, Satesh Kumar Annals of Medicine.2023;[Epub] CrossRef
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis Sagar Dholariya, Siddhartha Dutta, Ragini Singh, Deepak Parchwani, Amit Sonagra, Mehul Kaliya Expert Opinion on Pharmacotherapy.2023; 24(18): 2187. CrossRef
Analysis of the management and therapeutic performance of diabetes mellitus employing special target Hong-Yan Sun, Xiao-Yan Lin World Journal of Diabetes.2023; 14(12): 1721. CrossRef
Zinc Chloride Enhances the Antioxidant Status, Improving the Functional and Structural Organic Disturbances in Streptozotocin-Induced Diabetes in Rats Irina Claudia Anton, Liliana Mititelu-Tartau, Eliza Gratiela Popa, Mihaela Poroch, Vladimir Poroch, Ana-Maria Pelin, Liliana Lacramioara Pavel, Ilie Cristian Drochioi, Gina Eosefina Botnariu Medicina.2022; 58(11): 1620. CrossRef
The Effectiveness of Eye Movement Desensitization and Reprocessing Therapy on Death Anxiety and Perceived Stress in Patients with Type 2 Diabetes Sh Valizadeh Shafagh, S Taklavi, R Kazemi Journal of Health and Care.2022; 24(3): 245. CrossRef
Original Article
Diabetes, Obesity and Metabolism Big Data Articles (National Health Insurance Service Database)
Background Metabolic abnormalities, such as impaired fasting glucose (IFG), are dynamic phenomena; however, it is unclear whether the timing of IFG exposure and cumulative exposure to IFG are related to cardiovascular disease (CVD) and mortality risk.
Methods Data were extracted from a nationwide population-based cohort in South Korea for adults (n=2,206,679) who were free of diabetes and had 4 years of consecutive health examination data. Fasting blood glucose levels of 100 to 125 mg/dL were defined as IFG, and the number of IFG diagnoses for each adult in the 4-year period was tabulated as the IFG exposure score (range, 0 to 4). Adults with persistent IFG for the 4-year period received a score of 4.
Results The median follow-up was 8.2 years. There were 24,820 deaths, 13,502 cases of stroke, and 13,057 cases of myocardial infarction (MI). IFG exposure scores of 1, 2, 3, and 4 were associated with all-cause mortality (multivariable-adjusted hazard ratio [aHR], 1.11; 95% confidence interval [CI], 1.08 to 1.15; aHR, 1.16; 95% CI, 1.12 to 1.20; aHR, 1.20; 95% CI, 1.15 to 1.25; aHR, 1.18; 95% CI, 1.11 to 1.25, respectively) compared with an IFG exposure score of 0. Adjusting for hypertension and dyslipidemia attenuated the slightly increased risk of MI or stroke associated with high IFG exposure scores, but significant associations for allcause mortality remained.
Conclusion The intensity of IFG exposure was associated with an elevated risk of all-cause mortality, independent of cardiovascular risk factors. The association between IFG exposure and CVD risk was largely mediated by the coexistence of dyslipidemia and hypertension.
Citations
Citations to this article as recorded by
Cumulative exposure to impaired fasting glucose and gastrointestinal cancer risk: A nationwide cohort study Byeong Yun Ahn, Bokyung Kim, Sanghyun Park, Sang Gyun Kim, Kyungdo Han, Soo‐Jeong Cho Cancer.2024; 130(10): 1807. CrossRef
Diabetes severity and the risk of depression: A nationwide population-based study Yunjung Cho, Bongsung Kim, Hyuk-Sang Kwon, Kyungdo Han, Mee Kyoung Kim Journal of Affective Disorders.2024; 351: 694. CrossRef
Triglyceride-glucose index is associated with the risk of impaired fasting glucose in Chinese elderly individuals Jie Liu, Feng Yi, Kai Duan, Haibo Liu Scientific Reports.2024;[Epub] CrossRef
A nationwide cohort study on diabetes severity and risk of Parkinson disease Kyungdo Han, Bongsung Kim, Seung Hwan Lee, Mee Kyoung Kim npj Parkinson's Disease.2023;[Epub] CrossRef
Diabetes severity is strongly associated with the risk of active tuberculosis in people with type 2 diabetes: a nationwide cohort study with a 6-year follow-up Ji Young Kang, Kyungdo Han, Seung-Hwan Lee, Mee Kyoung Kim Respiratory Research.2023;[Epub] CrossRef
Construction and Validation of a Model for Predicting Impaired Fasting Glucose Based on More Than 4000 General Population Cuicui Wang, Xu Zhang, Chenwei Li, Na Li, Xueni Jia, Hui Zhao International Journal of General Medicine.2023; Volume 16: 1415. CrossRef
Factors Affecting High Body Weight Variability Kyungdo Han, Mee Kyoung Kim Journal of Obesity & Metabolic Syndrome.2023; 32(2): 163. CrossRef
Exposure to perfluoroalkyl and polyfluoroalkyl substances and risk of stroke in adults: a meta-analysis Min Cheol Chang, Seung Min Chung, Sang Gyu Kwak Reviews on Environmental Health.2023;[Epub] CrossRef
Cumulative effect of impaired fasting glucose on the risk of dementia in middle-aged and elderly people: a nationwide cohort study Jin Yu, Kyu-Na Lee, Hun-Sung Kim, Kyungdo Han, Seung-Hwan Lee Scientific Reports.2023;[Epub] CrossRef
A Longitudinal Retrospective Observational Study on Obesity Indicators and the Risk of Impaired Fasting Glucose in Pre- and Postmenopausal Women Myung Ji Nam, Hyunjin Kim, Yeon Joo Choi, Kyung-Hwan Cho, Seon Mee Kim, Yong-Kyun Roh, Kyungdo Han, Jin-Hyung Jung, Yong-Gyu Park, Joo-Hyun Park, Do-Hoon Kim Journal of Clinical Medicine.2022; 11(10): 2795. CrossRef
Current Trends of Big Data Research Using the Korean National Health Information Database Mee Kyoung Kim, Kyungdo Han, Seung-Hwan Lee Diabetes & Metabolism Journal.2022; 46(4): 552. CrossRef
Lipid cutoffs for increased cardiovascular disease risk in non-diabetic young people Mee Kyoung Kim, Kyungdo Han, Hun-Sung Kim, Kun-Ho Yoon, Seung-Hwan Lee European Journal of Preventive Cardiology.2022; 29(14): 1866. CrossRef
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim Journal of Lipid and Atherosclerosis.2022; 11(3): 288. CrossRef
Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk Seohyun Kim, Gyuri Kim, Jae Hyeon Kim Scientific Reports.2022;[Epub] CrossRef
Continuous glucose monitors (CGMs) have suddenly become part of routine care in many hospitals. The coronavirus disease 2019 (COVID-19) pandemic has necessitated the use of new technologies and new processes to care for hospitalized patients, including diabetes patients. The use of CGMs to automatically and remotely supplement or replace assisted monitoring of blood glucose by bedside nurses can decrease: the amount of necessary nursing exposure to COVID-19 patients with diabetes; the amount of time required for obtaining blood glucose measurements, and the amount of personal protective equipment necessary for interacting with patients during the blood glucose testing. The United States Food and Drug Administration (FDA) is now exercising enforcement discretion and not objecting to certain factory-calibrated CGMs being used in a hospital setting, both to facilitate patient care and to obtain performance data that can be used for future regulatory submissions. CGMs can be used in the hospital to decrease the frequency of fingerstick point of care capillary blood glucose testing, decrease hyperglycemic episodes, and decrease hypoglycemic episodes. Most of the research on CGMs in the hospital has focused on their accuracy and only recently outcomes data has been reported. A hospital CGM program requires cooperation of physicians, bedside nurses, diabetes educators, and hospital administrators to appropriately select and manage patients. Processes for collecting, reviewing, storing, and responding to CGM data must be established for such a program to be successful. CGM technology is advancing and we expect that CGMs will be increasingly used in the hospital for patients with diabetes.
Citations
Citations to this article as recorded by
Accuracy and Safety of the 15-Day CareSens Air Continuous Glucose Monitoring System Kyung-Soo Kim, Seung-Hwan Lee, Won Sang Yoo, Cheol-Young Park Diabetes Technology & Therapeutics.2024; 26(4): 222. CrossRef
Glucose management in critically ill adults: A qualitative study from the experiences of health care providers Miao Huang, Li Yang, Chuanlai Zhang, Xiuni Gan Heliyon.2024; 10(3): e24545. CrossRef
Summary of clinical investigation plan for The DIATEC trial: in-hospital diabetes management by a diabetes team and continuous glucose monitoring or point of care glucose testing – a randomised controlled trial Mikkel Thor Olsen, Carina Kirstine Klarskov, Ulrik Pedersen-Bjergaard, Katrine Bagge Hansen, Peter Lommer Kristensen BMC Endocrine Disorders.2024;[Epub] CrossRef
Nurses’ practice of metabolic monitoring for patients on antipsychotics in Lesotho Relebohile P. Matete, Libuseng M. Rathobei South African Journal of Psychiatry.2024;[Epub] CrossRef
Diabetes Management in Transition: Market Insights and Technological Advancements in CGM and Insulin Delivery Tae Sang Yu, Soojeong Song, Junwoo Yea, Kyung‐In Jang Advanced Sensor Research.2024;[Epub] CrossRef
The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record Juan Espinoza, Nicole Y. Xu, Kevin T. Nguyen, David C. Klonoff Journal of Diabetes Science and Technology.2023; 17(2): 495. CrossRef
Staff knowledge, attitudes and practices regarding glycaemic management in adult intensive care units: A national survey Miao Huang, Ruiqi Yang, Chuanlai Zhang, Xiuni Gan Nursing in Critical Care.2023; 28(6): 931. CrossRef
Continuous Glucose Monitoring for Patients with COVID-19 Pneumonia: Initial Experience at a Tertiary Care Center Adrian G. Dumitrascu, Michelle F. Perry, Rebecca J. Boone, Maria P. Guzman, Razvan M. Chirila, Allyson W. McNally, Dorin T. Colibaseanu, Shon E. Meek, Colleen T. Ball, Launia J. White, Ana-Maria Chindris Endocrine Practice.2023; 29(3): 155. CrossRef
Use of Continuous Glucose Monitors to Manage Type 1 Diabetes Mellitus: Progress, Challenges, and Recommendations Jared G Friedman, Zulma Cardona Matos, Emily D Szmuilowicz, Grazia Aleppo Pharmacogenomics and Personalized Medicine.2023; Volume 16: 263. CrossRef
Type 1 Diabetes Overview and Perioperative Management Grace B. Nelson, Kathryn M. Sumpter Orthopedic Clinics of North America.2023; 54(3): 287. CrossRef
Real-Time Continuous Glucose Monitoring in the Hospital: A Real-World Experience Samantha R. Spierling Bagsic, Addie L. Fortmann, Rebekah Belasco, Alessandra Bastian, Suzanne Lohnes, Anna Ritko, Haley Sandoval, Mariya Chichmarenko, Emily C. Soriano, Laura Talavera, Athena Philis-Tsimikas Journal of Diabetes Science and Technology.2023; 17(3): 656. CrossRef
Implementation of Continuous Glucose Monitoring in Critical Care: A Scoping Review Eileen R. Faulds, Kathleen M. Dungan, Molly McNett Current Diabetes Reports.2023; 23(6): 69. CrossRef
Clinical Use of Continuous Glucose Monitoring in Critically Ill Pediatric Patients with Diabetic Ketoacidosis Esther Park, Minsun Kim Diabetes Technology & Therapeutics.2023; 25(8): 529. CrossRef
Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality Ji Yoon Kim, Jee Hee Yoo, Jae Hyeon Kim Diabetes Technology & Therapeutics.2023; 25(12): 883. CrossRef
A randomized trial of continuous glucose monitoring to improve post‐transplant glycemic control Nicholas Jandovitz, Sam J. George, Mersema Abate, Adam M. Kressel, Alexandra C. Bolognese, Lawrence Lau, Vinay Nair, Elliot Grodstein Clinical Transplantation.2023;[Epub] CrossRef
More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data Richard M. Bergenstal, Gregg D. Simonson, Lutz Heinemann Journal of Diabetes Science and Technology.2022; 16(1): 3. CrossRef
Continuous glucose monitoring in the hospital: an update in the era of COVID-19 Chikara Gothong, Lakshmi G. Singh, Medha Satyarengga, Elias K. Spanakis Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(1): 1. CrossRef
Breakthrough technology for in-hospital glucose monitoring David Kerr, David Klonoff The Lancet Diabetes & Endocrinology.2022; 10(5): 304. CrossRef
The Role of the Diabetes Care and Education Specialist in the Hospital Setting
The Science of Diabetes Self-Management and Care.2022; 48(3): 184. CrossRef
Real-Time Monitoring of Blood Parameters in the Intensive Care Unit: State-of-the-Art and Perspectives Rebecca Bockholt, Shaleen Paschke, Lars Heubner, Bergoi Ibarlucea, Alexander Laupp, Željko Janićijević, Stephanie Klinghammer, Sascha Balakin, Manfred F. Maitz, Carsten Werner, Gianaurelio Cuniberti, Larysa Baraban, Peter Markus Spieth Journal of Clinical Medicine.2022; 11(9): 2408. CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon Frontiers in Endocrinology.2022;[Epub] CrossRef
Stress-Induced Hyperglycemia: Consequences and Management Deepanjali Vedantam, Devyani S Poman, Lakshya Motwani, Nailah Asif, Apurva Patel, Krishna Kishore Anne Cureus.2022;[Epub] CrossRef
Hospital Diabetes Meeting 2022 Jingtong Huang, Andrea M. Yeung, Kevin T. Nguyen, Nicole Y. Xu, Jean-Charles Preiser, Robert J. Rushakoff, Jane Jeffrie Seley, Guillermo E. Umpierrez, Amisha Wallia, Andjela T. Drincic, Roma Gianchandani, M. Cecilia Lansang, Umesh Masharani, Nestoras Math Journal of Diabetes Science and Technology.2022; 16(5): 1309. CrossRef
Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study Hun Jee Choe, Eun-Jung Rhee, Jong Chul Won, Kyong Soo Park, Won-Young Lee, Young Min Cho Diabetes Care.2022; 45(10): 2224. CrossRef
The Devil Is in the Details: Use, Limitations, and Implementation of Continuous Glucose Monitoring in the Inpatient Setting Rebecca Rick Longo, Renu Joshi Diabetes Spectrum.2022; 35(4): 405. CrossRef
Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives. The categories of anti-diabetic medications expanded from a few to numerous, enabling clinicians to personalize diabetes care and treatment. Thanks to rapid growth in the field of science and medical engineering, newer treatment options are coming to the market with various advantages and disadvantages to be aware of. Therefore, clinicians should rapidly adopt new trends based on guidelines and data from many clinical trials in the field of diabetes. In the treatment of dyslipidemia, trends and guidelines are changing every year, and novel therapies are being developed. In this review, we would like to summarize the major achievements in clinical medicine in 2020 in the field of diabetes mellitus and dyslipidemia.
Citations
Citations to this article as recorded by
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Effects of exercise initiation and smoking cessation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular outcomes Mee Kyoung Kim, Kyungdo Han, Bongsung Kim, Jinyoung Kim, Hyuk-Sang Kwon Scientific Reports.2022;[Epub] CrossRef
Combined Effects of Obesity and Dyslipidaemia on the Prevalence of Diabetes Amongst Adults Aged ≥45 Years: Evidence from a Nationally Representative Cross-Sectional Study Simin Zhang, Donghan Sun, Xiaoyi Qian, Li Li, Wenwen Wu International Journal of Environmental Research and Public Health.2022; 19(13): 8036. CrossRef
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim Journal of Lipid and Atherosclerosis.2022; 11(3): 288. CrossRef
We live in a digital world where a variety of wearable medical devices are available. These technologies enable us to measure our health in our daily lives. It is increasingly possible to manage our own health directly through data gathered from these wearable devices. Likewise, healthcare professionals have also been able to indirectly monitor patients’ health. Healthcare professionals have accepted that digital technologies will play an increasingly important role in healthcare. Wearable technologies allow better collection of personal medical data, which healthcare professionals can use to improve the quality of healthcare provided to the public. The use of continuous glucose monitoring systems (CGMS) is the most representative and desirable case in the adoption of digital technology in healthcare. Using the case of CGMS and examining its use from the perspective of healthcare professionals, this paper discusses the necessary adjustments required in clinical practices. There is a need for various stakeholders, such as medical staff, patients, industry partners, and policy-makers, to utilize and harness the potential of digital technology.
Citations
Citations to this article as recorded by
Managing Talent Among Healthcare Human Resource: Strategies for a New Normal Divya Aggarwal, Vijit Chaturvedi, Anandhi Ramachandran, Taniya Singh Journal of Health Management.2024; 26(2): 384. CrossRef
Current status of remote collaborative care for hypertension in medically underserved areas Seo Yeon Baik, Kyoung Min Kim, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2024;[Epub] CrossRef
Using medical big data for clinical research and legal considerations for the protection of personal information: the double-edged sword Raeun Kim, Jiwon Shinn, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 8. CrossRef
Diverse perspectives on remote collaborative care for chronic disease management Seo Yeon Baik, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 26. CrossRef
Expectations and concerns regarding medical advertisements via large commercial medical platform advertising companies: a legal perspective Raeun Kim, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2024; 6(2): 48. CrossRef
Patent analysis of digital sensors for continuous glucose monitoring Olena Litvinova, Magdalena Eitenberger, Aylin Bilir, Andy Wai Kan Yeung, Emil D. Parvanov, ArunSundar MohanaSundaram, Jarosław Olav Horbańczuk, Atanas G. Atanasov, Harald Willschke Frontiers in Public Health.2023;[Epub] CrossRef
Personalized Nutrition 2020: Proceedings from the American Nutrition Association’s 61st Annual Summit Victoria A. Y. Behm, Corinne L. Bush Journal of the American College of Nutrition.2021; 40(4): 397. CrossRef
Towards Telemedicine Adoption in Korea: 10 Practical Recommendations for Physicians Hun-Sung Kim Journal of Korean Medical Science.2021;[Epub] CrossRef
Perceptron: Basic Principles of Deep Neural Networks Eung-Hee Kim, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2021; 3(3): 64. CrossRef
Lack of Acceptance of Digital Healthcare in the Medical Market: Addressing Old Problems Raised by Various Clinical Professionals and Developing Possible Solutions Jong Il Park, Hwa Young Lee, Hyunah Kim, Jisan Lee, Jiwon Shinn, Hun-Sung Kim Journal of Korean Medical Science.2021;[Epub] CrossRef
Digital health and diabetes: experience from India Jothydev Kesavadev, Gopika Krishnan, Viswanathan Mohan Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110546. CrossRef
Background Coronavirus disease 2019 (COVID-19) has become a global pandemic, which prompts a consensus for the necessity to seek risk factors for this critical disease. Risk factors affecting mortality of the disease remain elusive. Diabetes and hyperglycemia are known to negatively affect a host’s antiviral immunity. We evaluated the relationship between a history of diabetes, fasting plasma glucose (FPG) levels and mortality among severely ill patients with COVID-19.
Methods This was a retrospective cohort study that assessed 106 adult inpatients (aged ≥18 years) from two tertiary hospitals in Daegu, South Korea. The participants were transferred to tertiary hospitals because their medical condition required immediate intensive care. The demographic and laboratory data were compared between COVID-19 patients who survived and those who did not.
Results Compared with the survivor group, age, and the proportions of diabetes, chronic lung disease and FPG were significantly higher in the deceased group. In the Cox proportional hazards regression model for survival analysis, FPG level and age were identified as significant predictors of mortality (P<0.05). The threshold values for predicting high mortality were age >68 years and FPG of 168 mg/dL, respectively. Among those without diabetes, high FPG remained a significant predictor of mortality (P<0.04).
Conclusion High FPG levels significantly predicted mortality in COVID-19, regardless of a known history of diabetes. These results suggest intensive monitoring should be provided to COVID-19 patients who have a high FPG level.
Citations
Citations to this article as recorded by
Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study Han Na Jang, Sun Joon Moon, Jin Hyung Jung, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee Endocrinology and Metabolism.2024; 39(3): 479. CrossRef
Testing AI Predictions that Hyperglycemia-Induced Non-Enzymatic Glycation of Immune System Proteins Impairs Diabetic Immunity Thomas Turkette, Andrew Decker, Robert Root-Bernstein Computational and Structural Biotechnology Reports.2024; : 100015. CrossRef
Fasting Plasma Glucose Levels at the Time of Admission Predict 90-Day
Mortality in Patients with Viral Pneumonia. A Prospective Study Jie Xu, Jianyu Zhao, Liyuan Wu, Xinxin Lu Experimental and Clinical Endocrinology & Diabetes.2023; 131(05): 290. CrossRef
Influence of Fasting Plasma Glucose Level on Admission of COVID-19 Patients: A Retrospective Study Yingying Zhao, Huichun Xing, Yong Xu Journal of Diabetes Research.2022; 2022: 1. CrossRef
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris Frontiers in Clinical Diabetes and Healthcare.2022;[Epub] CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon Frontiers in Endocrinology.2022;[Epub] CrossRef
Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis Abraham Degarege, Zaeema Naveed, Josiane Kabayundo, David Brett-Major Pathogens.2022; 11(5): 563. CrossRef
Global, Regional and National Burden of Cancers Attributable to High Fasting Plasma Glucose in 204 Countries and Territories, 1990-2019 Saeid Safiri, Seyed Aria Nejadghaderi, Nahid Karamzad, Jay S. Kaufman, Kristin Carson-Chahhoud, Nicola Luigi Bragazzi, Mark J. M. Sullman, Mohammad Reza Beyranvand, Mohammad Ali Mansournia, Amir Almasi-Hashiani, Gary S. Collins, Ali-Asghar Kolahi Frontiers in Endocrinology.2022;[Epub] CrossRef
COVID-19 and diabetes—Two giants colliding: From pathophysiology to management Maria Chiara Pelle, Isabella Zaffina, Michele Provenzano, Giovenale Moirano, Franco Arturi Frontiers in Endocrinology.2022;[Epub] CrossRef
Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients With COVID-19 Alon Y. Mazori, Ilana Ramer Bass, Lili Chan, Kusum S. Mathews, Deena R. Altman, Aparna Saha, Howard Soh, Huei Hsun Wen, Sonali Bose, Emily Leven, Jing Gennie Wang, Gohar Mosoyan, Pattharawin Pattharanitima, Giampaolo Greco, Emily J. Gallagher Endocrine Practice.2021; 27(2): 95. CrossRef
The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis Li Zhang, Jie Hou, Fu-Zhe Ma, Jia Li, Shuai Xue, Zhong-Gao Xu Archives of Virology.2021; 166(8): 2071. CrossRef
Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis M Zuin, G Rigatelli, C Bilato, C Cervellati, G Zuliani, L Roncon QJM: An International Journal of Medicine.2021; 114(6): 390. CrossRef
National early warning score on admission as risk factor for invasive mechanical ventilation in COVID-19 patients Min Cheol Chang, Tae Uk Kim, Donghwi Park Medicine.2021; 100(19): e25917. CrossRef
Thyroid Hormone Profile and Its Prognostic Impact on the Coronavirus Disease 2019 in Korean Patients Jiyeon Ahn, Min Kyung Lee, Jae Hyuk Lee, Seo Young Sohn Endocrinology and Metabolism.2021; 36(4): 769. CrossRef
Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies Yahya Mahamat-Saleh, Thibault Fiolet, Mathieu Edouard Rebeaud, Matthieu Mulot, Anthony Guihur, Douae El Fatouhi, Nasser Laouali, Nathan Peiffer-Smadja, Dagfinn Aune, Gianluca Severi BMJ Open.2021; 11(10): e052777. CrossRef
COVID-19 und Diabetes: Folgen der Pandemie Baptist Gallwitz, Wolfgang Rathmann Deutsches Ärzteblatt Online.2021;[Epub] CrossRef
Incidence of Post-Traumatic Stress Disorder after Coronavirus Disease Min Cheol Chang, Donghwi Park Healthcare.2020; 8(4): 373. CrossRef
BACKGROUND Self monitoring of blood glucose plays an important role in the management of diabetes. However, traditional finger prick testing causes pain and so compliance with self monitoring of blood glucose is usually poor. Using an alternative site for sampling may reduce the level of pain and be beneficial for improving the compliance of diabetic patients. We evaluated the accuracy and acceptability of blood glucose testing from the forearm by analyzing the performance of the CareSens(R) (i-Sens, Inc. Korea) device for diabetic patients. METHODS: We measured the glucose level at the forearm by use of CareLance(R) (vaccum assisted lancing device) and also at the finger tip simultaneously by use of the CareSens(R) device at fasting and postprandial 2 hours, respectively. At the same time, the glucose levels of venous samples were checked by the laboratory method (BIOSEN 5030, EKF, Germany) and compared with those glucose level measured by the CareSens(R) device. We also checked the ease of use of the CareLance(R) and the associated pain of the patients by means of a visual analogue scale (VAS) at the time of blood sampling. RESULTS: The glucose level obtained from the forearm and finger tip correlated well with that from the laboratory method, respectively. Error grid analysis showed that 100% of the measurements were clinically acceptable; forearm blood glucose testing by use of CareLance(R) was less painful and it was as easy to use as the finger prick (P < 0.05 and P = 0.04, respectively). CONCLUSION: Forearm testing is an acceptable alternative to finger prick testing for measuring blood glucose in diabetic patients.
Citations
Citations to this article as recorded by
Accuracy Evaluation of the Alternative Site Blood Glucose Test Using Error Grid Kyung-Soon Park, Eun-Jong Cha Journal of Biomedical Engineering Research.2011; 32(1): 25. CrossRef